AACR 2019: Novel therapeutic approach for vulnerable patients with esophageal cancer
The experimental oncolytic adenovirus telomelysin (OBP-301) in combination with radiotherapy was safe and showed early clinical efficacy in vulnerable patients with esophageal cancer. This a phase I trial presented at the AACR 2019 Annual Meeting shows.
The oncolytic adenovirus telomelysin (OBP-301) is an attenuated adenovirus which contains the human telomerase reverse transcriptase (hTERT) promoter to regulate viral replication. Infection with telomelysin causes cell lysis in various cancer cells.
Um den Beitrag in voller Länge zu lesen, müssen Sie sich einloggen oder kostenlos registrieren.
More from this topic:
AACR 2019: Pembrolizumab combined with chemotherapy improves survival of patients with NSCLC with brain and liver metastases
15. 04. 2019
AACR 2019: Genetic risk factor for strokes following cranial radiation therapy for childhood cancers identified
03. 04. 2019